Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2021 Dec 7;15(1):101302. doi: 10.1016/j.tranon.2021.101302

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© 2021 The Authors. Published by Elsevier Inc.

This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).

PMC Copyright notice

Fig. 3 — Suppressive effect of nafamostat mesylate on metastasis of endocrine-resistant estrogen receptor-positive breast cancer. (A) Analysis of migration activity of MCF7-TamR (upper) and FulR (lower) cells treated with 30 μM of NM by in vitro Transwell-dependent migration assay. (B) Quantitative analysis of migration activity of NM-treated MCF7-TamR (upper) and FulR (lower) cells (C) Analysis of the invasive activity of MCF7-TamR (upper) and FulR (lower) cells treated with 30 μM of NM, assessed using in vitro invasive assays. (D) Quantitative analysis of the invasive activity of NM-treated MCF7-TamR (upper) and FulR (lower) cells. (E) Levels of markers for epithelial-mesenchymal transition in MCF7-TamR (upper) and MCF7-FulR (lower) cells treated with serial doses of NM, assessed using western blot analysis with specific antibodies. Data are represented as the mean ± SEM for biological triplicate experiments. *P < 0.01, compared with the results for untreated MCF7-FulR and MCF7-TamR cells.